# STC-1010

Source: https://onco.cc/drugs/stc-1010/  
OnCo record `stc-1010` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

STC-1010 is an experimental off-the-shelf in vivo immunotherapy from stimulated, inactivated allogeneic cancer cell lines from Brenus Pharma, in phase 1 trials for unresectable locally advanced or metastatic pMMR/MSS colorectal cancer.

## Summary

STC-1010 is an off-the-shelf in vivo immunotherapy from stimulated, inactivated allogeneic cancer cell lines (the company calls it an in vivo DC-engager) from Brenus Pharma. Made from selected allogeneic human cancer cell lines (Stimulated-Ghost-Cells); the company describes it as an in vivo DC-engager designed to make immunologically 'cold' tumours visible to immune cells. It is given with oral low-dose cyclophosphamide, with or without GM-CSF, alongside first-line chemotherapy. Its furthest stage is phase 1, for unresectable locally advanced or metastatic pMMR/MSS colorectal cancer. ClinicalTrials.gov registers it in one study linked below. Phase I/IIa BreAK CRC-001 (NCT06934538, registry PHASE1/PHASE2, recruiting); phase Ia dose-escalation data at ESMO 2026 (press release 23 Oct 2026). FDA accepted the IND in May 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: STC-1010
- Modality: Off-the-shelf in vivo immunotherapy from stimulated, inactivated allogeneic cancer cell lines (the company calls it an in vivo DC-engager)
- Mechanism: Made from selected allogeneic human cancer cell lines (Stimulated-Ghost-Cells); the company describes it as an in vivo DC-engager designed to make immunologically 'cold' tumours visible to immune cells. It is given with oral low-dose cyclophosphamide, with or without GM-CSF, alongside first-line chemotherapy.

## Sources

- Brenus Pharma: brenus-pharma.com: https://www.brenus-pharma.com/science-innovation
- Brenus Pharma: brenus-pharma.com: https://www.brenus-pharma.com/articles/brenus-pharma-esmo-2026-stc-1010-phase-1a-results
- Brenus Pharma: brenus-pharma.com: https://www.brenus-pharma.com/articles/brenus-pharma-esmo-2026-stc-1010-phase-1a-results
- Brenus Pharma: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06934538
- ClinicalTrials.gov: trials of STC-1010: https://clinicaltrials.gov/search?intr=STC-1010

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- companies: [Brenus Pharma](https://onco.cc/companies/brenus-pharma/)
- trials: [First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct06934538/)

---
JSON: https://onco.cc/api/v1/entities/stc-1010.json